The study examined the use of the IsoRay’s seeds for treating recurrent aggressive meningiomas by applying seeds embedded in collagen tiles directly to brain tissue after tumor removal. IsoRay called the technique the “GammaTile” approach, but clarified that it is not commercially available.
A total of 95% of the treated tumors showed no radiographic evidence of regrowth of the tumor at the operative site, and the incidence of radiation side effects occurred in only 10% of treatments, the company said.
“These are aggressive meningiomas that have recurred in patients despite previous surgery and radiation. These tumors pose a serious challenge to physicians due to their presence in the brain and the failure of prior treatments. Use of the Cesium-131 tiles, which were able to be implanted very quickly at the time of surgery, and starting radiation therapy at the time of resection as opposed to weeks after resection when using external beam radiation were advantages of our novel approach. We are seeing 95% local control of the treated tumors in our study using surgery and Cesium implants. In addition, we observed a very low rate of radiation injury, which has been a major concern in the past, for patients who have undergone multiple treatments for their brain tumors,” Dr. David Brachman of the Barrow Neurological Institute said in a press release.
A total of 16 patients with 20 tumors were examined in the trial, and all patients in the study had recurrences of tumors after prior surgery and external beam radiation treatment and were considered to be at an increased risk for additional recurrence.
“We are encouraged to see this preliminary response to these challenging cancers. We are pleased Dr. Brachman had the opportunity to present his findings at such a prestigious forum of his peers,” CEO Tom LaVoy said in a prepared statement.
The post IsoRay touts brachytherapy brain cancer trial appeared first on MassDevice.
from MassDevice http://ift.tt/28QJuw9
Cap comentari:
Publica un comentari a l'entrada